Predicted Trait | |
Reported Trait | Prostate Cancer |
Mapped Trait(s) | prostate carcinoma (EFO_0001663) |
Score Construction | |
PGS Name | PRS103_PrCa |
Variants | |
Original Genome Build | GRCh37 |
Number of Variants | 103 |
Development Method | |
Name | Known susceptibility loci (genome-wide significant SNPs) |
Parameters | Sum of log(ORs) |
PGS Source | |
PGS Catalog Publication (PGP) ID | PGP000034 |
Citation (link to publication) | Lecarpentier J et al. J Clin Oncol (2017) |
Study Identifiers | Sample Numbers | Sample Ancestry |
---|---|---|
GWAS Catalog: GCST002606 EuropePMC: 25217961 |
67,543 individuals | European |
GWAS Catalog: GCST002606 EuropePMC: 25217961 |
2,080 individuals | Hispanic or Latin American |
GWAS Catalog: GCST002606 EuropePMC: 25217961 |
6,954 individuals | East Asian |
GWAS Catalog: GCST002606 EuropePMC: 25217961 |
10,463 individuals | Sub-Saharan African, African American or Afro-Caribbean |
PGS Performance Metric ID (PPM ID) |
PGS Sample Set ID (PSS ID) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
PGS Classification Metrics | Other Metrics | Covariates Included in the Model | PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|
PPM000123 | PSS000075 | PGP000034 Lecarpentier J et al. (2017) | Reported Trait: Prostate cancer in male carriers of BRCA1/2 mutations | OR: 1.56 [1.35, 1.81] | AUROC: 0.62 [0.58, 0.66] | — | 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2 | — |
PPM000124 | PSS000077 | PGP000034 Lecarpentier J et al. (2017) | Reported Trait: Low prostate cancer aggressiveness (Gleason score < 7) | OR: 1.44 [1.1, 1.87] | — | — | 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2 | — |
PPM000125 | PSS000076 | PGP000034 Lecarpentier J et al. (2017) | Reported Trait: High prostate cancer aggressiveness (Gleason score ≥ 7) | OR: 1.67 [1.37, 2.04] | — | — | 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2 | — |
PGS Sample Set ID (PSS ID) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS000076 | — | — | [ ,
100.0 % Male samples |
— | European | Self-reported European ancestry | 37 cohorts
|
— |
PSS000077 | — | — | [ ,
100.0 % Male samples |
— | European | Self-reported European ancestry | 37 cohorts
|
— |
PSS000075 | Breast and prostate cancer cases were defined on the basis of age at diagnosis, whichever occurred first. If breast and prostate cancer occurred at the same time, individuals were treated as patients with breast cancer. | — | [ ,
100.0 % Male samples |
— | European | Self-reported European ancestry | 37 cohorts
|
— |